Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

NCT00044668 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of the medication AC2993 on blood sugar control in adults with type 2 diabetes who are already taking metformin, sulfonylurea, or a combination of both.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 155 people

Who can join Ages 20–75 · all sexes

Timeline Started 2002-08 · est. completion 2005-09

Where 3 sites · Hungary

What this study is testing ClinicalTrials.gov NCT00044668 ↗

Description as written by the study sponsor.

This multi-center, open-label study is designed to examine the effects on long-term glucose control and safety of AC2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea combination.

Treatments tested

AC2993 also known as synthetic exendin-4 Drug

Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.

Main thing measured	Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 24, Week 52, and to each intermediate visit
Sponsor	AstraZeneca
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00044668 ↗